The purpose of this paper was to compare the concentration and size distribution of cell-free DNA (cfDNA) and epidermal growth factor receptor (EGFR) mutation status between specimens collected from male and female, stage III and stage IV, and adenocarcinoma (ADK) and non-ADK non-small cell lung cancer (NSCLC) patients. Additionally, the authors investigated the sensitivity of cfDNA for mutations in biopsy specimens by comparing EGFR mutation status in matched plasma and biopsy specimens from patients with NSCLC.
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
González de Aledo-Castillo JM, Arcocha A, Victoria I, Martinez-Puchol AI, Sánchez C, Jares P, Rodríguez GF, Viñolas N, Reyes R, Reguart N, Puig-Butillé JA
Purpose
Conclusion
The concentration and fragmentation pattern of cfDNA was not significantly affected by patient gender or smoking history. Median total cfDNA, cfDNA between 100-250 bp, and cfDNA between 250-700 bp were all comparable between ADK patients and all other NSCLC patients. Patients with stage IV NSCLC had higher concentrations of cfDNA, percentage of cfDNA 100-250 bp, and percentage of cfDNA 250-700 bp but significance depended on diagnosis.
EGFR mutations were identified in 24.3% of patients with SQIs ranging from 2.1 to 25.0. EGFR mutations were identified at a higher prevalence in plasma from women than men and non-smokers than past or current smokers but in a comparable percentage of stage III and stage IV patients. There was a very strong correlation in concentration of cfDNA between vials collected during the same blood draw and the same EGFR status was found in 54 of 56 patients. The two discrepant cases both harbored L858R mutations with semiquantitative index (SQI) values of 5.4 and 6.1, respectively. SQI for the EGFR mutations was not correlated with cfDNA concentration or disease stage but were higher for Ex19Del EGFR than L858R EGFR.
The sensitivity of plasma cfDNA testing for EGFR mutations in tumor biopsy was 78.3% and the specificity was 100% and was not affected by plasma cfDNA concentration.
Studies (2)
Purpose
The purpose of this study was to compare the concentration and size distribution of cfDNA and EGFR mutation status between specimens collected from male and female, stage III and stage IV, and ADK and non-ADK NSCLC patients. Peripheral whole blood was obtained from 173 NSCLC patients who were TKI naïve into K2EDTA tubes. Plasma was obtained by centrifugation at 1,600 x g for 10 minutes and stored at -20°C after 15-20 min of upright storage at room temperature. cfDNA was isolated using the Cobas cfDNA Sample Preparation Kit and quantified by fluorometer. cfDNA fragment size was evaluated by bioanalyzer. EGFR mutation status was investigated using the Cobas EGFR Test.
Summary of Findings
The concentration and fragmentation pattern of cfDNA was not significantly affected by patient gender or smoking history. Median total cfDNA, cfDNA between 100-250 bp, and cfDNA between 250-700 bp were all comparable between ADK patients and all other NSCLC patients. Compared to stage III patients, stage IV patients had higher median cfDNA concentration (31.9 versus 13.1 ng/mL, P<0.0001) and percentage cfDNA between 100-250 bp (43% versus 33%, P=0.013) but comparable percentage of cfDNA between 250-700 bp (16% versus 14%, P>0.05). When broken down by diagnosis, patients with stage IV ADK had significantly higher concentration of cfDNA (29 ng/mL versus 13.1 ng/mL, P<0.001), percentage of cfDNA 100-250 bp (P=0.008), and percentage of cfDNA 250-700 bp (P=0.02). In contrast, while other NSCLC stage IV patients had higher cfDNA concentrations than stage III non-ADK NSCLC patients (41.1 ng/mL versus 12.8 ng/mL, P<0.0001), no difference in percentage of cfDNA 100-250 bp or 250-700 bp was found. A cutoff of >20.3 ng/mL cfDNA was 72.3% sensitive and 95% specific for the diagnosis of stage IV NSCLC but a cut-off of >50.5% 100–250 bp fragments was only 36.8% sensitive and 95% specific for the diagnosis of Stage IV NSCLC.
EGFR mutations were identified in 24.3% of patients with SQIs ranging from 2.1 to 25.0. EGFR mutations were identified at a higher prevalence in the plasma of women than men (3.5% versus 14.6%, P=0.002) and non-smokers than in past or current smokers (49.42%, versus 11.4%, P<0.0001) but a comparable percentage of stage III and stage IV patients (17.6% versus 25%). There was a very strong correlation in concentration cfDNA between vials collected during the same blood draw (r2=0.70) and the same EGFR status was found in 54 of 56 patients (96.5%). The two discrepant cases both harbored L858R mutations with SQI values of 5.4 and 6.1, respectively, and the mutation was detected in the vial with a non-significantly higher cfDNA concentration in both cases. SQI for the EGFR mutations was not correlated with cfDNA concentration or disease stage (P=0.28 and P=0.41, respectively). SQI values were higher for Ex19Del EGFR than L858R EGFR (113.6 versus 8.9, P=0.001).
Biospecimens
FluidPlasmaPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNAReal-time qPCRPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition AdenocarcinomaOther non-small cell lung cancerPreaquisition Other drugs Current smokerFormer smokerNever smokerPreaquisition Patient gender FemaleMalePreaquisition Prognostic factor Stage IIIStage IVReal-time qPCR Specific Targeted nucleic acid EGFR
Purpose
The purpose of this study was to investigate the sensitivity of cfDNA for mutations in biopsy specimens by comparing EGFR mutation status in matched plasma and biopsy specimens from patients with NSCLC. Peripheral K2EDTA whole blood was obtained from 104 NSCLC patients who had a prior biopsy in the previous two months. Plasma was obtained by centrifugation at 1,600 x g for 10 minutes and stored at -20°C after 15-20 min upright storage at room temperature. No details of biopsy collection, preservation, or storage were evaluated. cfDNA was isolated using the Cobas cfDNA Sample Preparation Kit and quantified by fluorometer. cfDNA fragments size was evaluated by bioanalyzer. EGFR mutation status was investigated in plasma using the Cobas EGFR Test and was previously determined in the biopsy by NGS (97 cases), Cobas EGFR test (5 cases), SCORPIONS and ARMS (1 case), and by 5’ nuclease assay in the final case.
Summary of Findings
The sensitivity of plasma cfDNA testing for EGFR mutations in tumor biopsy was 78.3% and the specificity was 100%. The discrepant cases included seven with EGFR mutations in tumor that were tested for but not detected in the plasma. There was no effect of plasma cfDNA concentration on the concordance.
Biospecimens
FluidPlasmaTissueLungPreservation Types
FrozenDiagnoses
NeoplasticCarcinomaPlatforms
DNAReal-time qPCRDNANext generation sequencingPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Biospecimen location PlasmaTumorReal-time qPCR Specific Targeted nucleic acid EGFR